Targeting PDE4 drives anti-inflammatory and antifibrotic effects, and Boehringer has been working on its own PDE4 inhibitor ...

An analysis of pooled data from two large finerenone trials identified key risk factors for hyperkalemia in patients with CKD ...

The global canine arthritis treatment market stands at a valuation of USD 2.50 billion in 2024. Global demand for canine arthritis treatment medications is predicted to rise at a CAGR of 4.20% and ...

The newly formed advisory board, which held its inaugural meeting last month, will identify opportunities to enhance scientific capabilities to ensure that OXB remains at the forefront of developing ...

The global biosimilars market growth is driven by increasing number of biosimilar approvals and rising number of biologics going off-patent.A biosimilar is a biological product that is similar to a ...

Nerandomilast slowed lung function decline in people with IPF and PPF after a year of treatment, according to data from two ...

and acknowledges the leading position China has achieved in many scientific areas", said David Preston, President and CEO of Boehringer Ingelheim Greater China.

Ascletis said it has data indicating denifanstat is 98% more effective at treating acne than sarecycline, and 178% better ...

Regulatory Evolution and Product Innovation: Regulatory frameworks governing OTC pet medications are evolving to ensure ...